Stockscreener 앱 받기
11.12
1.55%
0.17
시간 외 거래:
11.12
전일 마감가:
$10.95
열려 있는:
$10.83
하루 거래량:
643.04K
Relative Volume:
0.30
시가총액:
$788.41M
수익:
-
순이익/손실:
$-121.24M
주가수익비율:
-5.5112
EPS:
-2.0177
순현금흐름:
$-105.32M
1주 성능:
-2.63%
1개월 성능:
-7.41%
6개월 성능:
+166.03%
1년 성능:
+23.83%
1일 변동 폭
$10.66
$11.27
1주일 범위
$10.66
$11.71
52주 변동 폭
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
명칭
Omeros Corporation
전화
206-676-5000
주소
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
11.12 | 776.36M | 0 | -121.24M | -105.32M | -2.0177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-10 | 개시 | H.C. Wainwright | Buy |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2022-12-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-11-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-06-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-10-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2021-10-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-09-27 | 개시 | JP Morgan | Neutral |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-08-21 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2019-05-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 개시 | Seaport Global Securities | Buy |
| 2018-03-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-03-05 | 다운그레이드 | Needham | Buy → Hold |
| 2017-11-08 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 재확인 | Maxim Group | Buy |
| 2017-03-17 | 재확인 | Needham | Buy |
| 2016-11-16 | 재확인 | Wedbush | Outperform |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-06-03 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-02 | 재확인 | Needham | Buy |
| 2016-02-29 | 재확인 | Wedbush | Outperform |
| 2015-11-11 | 재확인 | Needham | Buy |
| 2015-08-18 | 재확인 | WBB Securities | Strong Buy |
| 2015-08-10 | 개시 | ROTH Capital | Buy |
모두보기
Omeros Corporation 주식(OMER)의 최신 뉴스
GeekWire Awards: Billion-dollar deals, rare IPO, pharma pact, and mega-round vie for Deal of the Year - GeekWire
Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
OMER SEC FilingsOmeros 10-K, 10-Q, 8-K Forms - Stock Titan
Is Omeros Corporation gaining market share2026 Valuation Update & Weekly High Potential Stock Alerts - baoquankhu1.vn
Omeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN
Omeros rises after pricing ~$22M stock offering - MSN
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - Stocktwits
Omeros: Yartemlea Can Own The Label And Still Split The Market (NASDAQ:OMER) - Seeking Alpha
Omeros (OMER) Expected to Announce Earnings on Tuesday - MarketBeat
Omeros (NASDAQ: OMER) CEO exercises 400,000 options with tax share withholding - Stock Titan
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - PharmiWeb.com
Omeros Corporation Announces Successful Primate Study in OncotoX-AML Drug Program - marketscreener.com
Omeros (OMER) Shows Promising Results in Early Cancer Treatment Study - GuruFocus
Why Omeros Corporation stock could be next big winnerJuly 2025 Setups & Smart Swing Trading Alerts - mfd.ru
Is Omeros Corporation stock positioned well for digital economyJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - mfd.ru
What risks investors should watch in Omeros Corporation stockWeekly Investment Report & Long-Term Safe Investment Plans - mfd.ru
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Omeros Achieves Commercial Milestone with First Approved Drug Launch - AD HOC NEWS
Macro Review: What is the long term forecast for Omeros Corporation stockStock Surge & Community Shared Stock Ideas - baoquankhu1.vn
Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions - Yahoo Finance
Omeros wins FDA nod for transplant therapy - MSN
Omeros Corporation (NASDAQ:OMER) Sees Large Growth in Short Interest - MarketBeat
EV Market: Is Omeros Corporation gaining market shareTrade Entry Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
Vanguard discloses 4.0M-share Omeros Corp (NASDAQ: OMER) position - Stock Titan
Omeros higher after first commercial sales of transplant therapy - MSN
Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com - Investing.com Australia
Big Money Moves: What is the implied volatility of Air Products and Chemicals IncWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Omeros Shares Rise After Starting Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Rises on First Shipments of Yartemlea - GuruFocus
Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ) - Seeking Alpha
OMER: D. Boral Capital Maintains Buy Rating with $36 Price Targe - GuruFocus
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital - MarketBeat
Omeros stock rises as first commercial YARTEMLEA shipments begin By Investing.com - Investing.com Canada
Omeros stock rises as first commercial YARTEMLEA shipments begin - Investing.com
Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA - GuruFocus
Omeros announces first commercial sales of Yartemlea - TipRanks
Omeros begins commercial distribution of TA-TMA treatment Yartemlea - Investing.com
Omeros Announces First Commercial Sales of YARTEMLEA® - Yahoo Finance
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Portfolio Update: Can Omeros Corporation maintain sales growthJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Omeros Corporation (OMER) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):